+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Table of Contents:
1. Executive summary
2. Market Introduction
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. Research Methodology
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. Market Dynamics
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. Market Factor Analysis
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS
6.1. Overview
6.2. Alpha blockers
6.3. 5- alpha reductase inhibitors
6.4. Phosphodiesterase-5 inhibitors
6.5. Others
7. GLOBAL Benign Prostatic Hyperplasia Treatment MARKET, BY Therapy
7.1. Overview
7.2. Mono drug therapy
7.3. Combination drug therapy
8. GLOBAL Benign Prostatic Hyperplasia Treatment MARKET, by Region
8.1. Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. India
8.4.3. Japan
8.4.4. South Korea
8.4.5. Australia
8.4.6. Rest of Asia-Pacific
8.5. Rest of the World
8.5.1. Middle East
8.5.2. Africa
8.5.3. Latin America
9. Competitive Landscape
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Benign Prostatic Hyperplasia Treatment Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Benign Prostatic Hyperplasia Treatment Market,
9.7. Key developments and Growth Strategies
9.7.1. New THERAPEUTICS CLASS Launch/Therapy Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2022
9.8.2. Major Players R&D Expenditure. 2022
10. Company ProfileS
10.1. Abbott Laboratories
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Therapeutics Class Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. AbbVie (Allergan Plc)
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Therapeutics Class Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Astellas Pharma Inc.
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Therapeutics Class Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Boehringer Ingelheim Pharma GmbH & Co. KG
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Therapeutics Class Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Eli Lilly and Company
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Therapeutics Class Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. GlaxoSmithKline plc.
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Therapeutics Class Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Therapeutics Class Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Pfizer Inc.
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Therapeutics Class Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Sanofi
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Therapeutics Class Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Teva Pharmaceutical Industries Limited
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Therapeutics Class Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
11. Appendix
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 Global Benign Prostatic Hyperplasia Treatment Market, Synopsis, 2018-2032
TABLE 2 Global Benign Prostatic Hyperplasia Treatment Market, Estimates & Forecast, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 5 North America Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 6 North America Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 7 North America Benign Prostatic Hyperplasia Treatment MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 8 U.S. Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 9 U.S. Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 10 Canada Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 11 Canada Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 12 Europe Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 13 Europe Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 14 Europe Benign Prostatic Hyperplasia Treatment MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 15 Germany Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 16 Germany Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 17 France Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 18 France Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 19 Italy Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 20 Italy Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 21 Spain Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 22 Spain Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 23 U.K Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 24 U.K Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 25 Rest of Europe Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 26 Rest of Europe Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 27 Asia Pacific Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 28 Asia Pacific Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 29 Asia Pacific Benign Prostatic Hyperplasia Treatment MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 30 Japan Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 31 Japan Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 32 China Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 33 China Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 34 India Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 35 India Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 36 Australia Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 37 Australia Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 38 south korea Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 39 south korea Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 40 Rest of asia-pacific Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 41 Rest of asia-pacific Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 42 Rest of WOrld Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 43 Rest of WOrld Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 44 Rest of WOrld Benign Prostatic Hyperplasia Treatment MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 45 Middle east Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 46 Middle east Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 47 Africa Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 48 Africa Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
TABLE 49 Latin america Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPEUTICS CLASS, 2018-2032 (USD BILLION)
TABLE 50 Latin america Benign Prostatic Hyperplasia Treatment MARKET, BY THERAPY, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 Research Process
FIGURE 2 Market Structure for the Global Benign Prostatic Hyperplasia Treatment Market
FIGURE 3 Market Dynamics for the Global Benign Prostatic Hyperplasia Treatment Market
FIGURE 4 Global Benign Prostatic Hyperplasia Treatment Market, Share (%), BY THERAPEUTICS CLASS, 2022
FIGURE 5 Global Benign Prostatic Hyperplasia Treatment Market, Share (%), BY THERAPY, 2022
FIGURE 6 Global Benign Prostatic Hyperplasia Treatment Market, Share (%), by Region, 2022
FIGURE 7 north AMERICA: Benign Prostatic Hyperplasia Treatment MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 Europe: Benign Prostatic Hyperplasia Treatment MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 Asia-Pacific: Benign Prostatic Hyperplasia Treatment MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 Rest of the world: Benign Prostatic Hyperplasia Treatment MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 Global Benign Prostatic Hyperplasia Treatment Market: Company Share Analysis, 2022 (%)
FIGURE 12 Abbott Laboratories: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 Abbott Laboratories: SWOT ANALYSIS
FIGURE 14 AbbVie (Allergan Plc): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 AbbVie (Allergan Plc): SWOT ANALYSIS
FIGURE 16 Astellas Pharma Inc.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 Astellas Pharma Inc.: SWOT ANALYSIS
FIGURE 18 Boehringer Ingelheim Pharma GmbH & Co. KG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 Boehringer Ingelheim Pharma GmbH & Co. KG: SWOT ANALYSIS
FIGURE 20 Eli Lilly and Company.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 Eli Lilly and Company.: SWOT ANALYSIS
FIGURE 22 GlaxoSmithKline plc.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 GlaxoSmithKline plc.: SWOT ANALYSIS
FIGURE 24 Merck & Co., Inc. (Merck Sharp & Dohme Corp): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 Merck & Co., Inc. (Merck Sharp & Dohme Corp): SWOT ANALYSIS
FIGURE 26 Pfizer Inc.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 Pfizer Inc.: SWOT ANALYSIS
FIGURE 28 Sanofi: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 Sanofi: SWOT ANALYSIS
FIGURE 30 Teva Pharmaceutical Industries Limited: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 Teva Pharmaceutical Industries Limited: SWOT ANALYSIS
Report Code :
RL6571
Published on :
Aug 2023
Request a Free Sample Report
Speak to Analyst